This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vasey, P. A. Articles by Cassidy, J. Search for Related Content PubMed PubMed Citation Articles by Vasey, P. A. Articles by Cassidy, J.

Phase I Clinical and Pharmacokinetic Study of 3'-Deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762)

Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT, United Kingdom [P. A. V., D. B., L. A., P. W., S. B. K.]; Pharmacia Farmitalia Carlo Erba, Via Carlo Imbonati 24, 20159 Milan, Italy [M. S-B., I. P., M. B., M. A. P.]; and Department of Oncology, University of Aberdeen, Aberdeen, United Kingdom [J. C.]

Methoxymorpholinyldoxorubicin (FCE 23762) is a novel, highly lipophilic doxorubicin analogue. It possesses potent in vitro and in vivo antitumor activity including efficacy in multidrug-resistant tumor cell lines. It is also metabolically activated in vivo resulting in an 80-fold increase in potency over the parent drug.

In this phase I study the drug was administered by i.v. bolus injection at 3-week intervals. Fifty-three patients with refractory solid tumors were treated; 133 courses of FCE 23762 were administered at doses ranging from 30 to 2250 µg/m². The dose limiting toxicity was reversible myelosuppression (granulocytopenia and thrombocytopenia), demonstrating a delayed nadir and recovery in comparison to doxorubicin. Other toxicities included transient elevation of hepatic transaminases, delayed and prolonged nausea and vomiting, mucositis, anorexia, fatigue, and diarrhea. Heavily pretreated patients demonstrated more myelosuppression than previously untreated patients at 1250 µg/m². No cardiotoxicity was observed. Four objective tumor responses were seen: one complete response in a patient with pelvic recurrence of cervical cancer; one partial response in a patient with cutaneous and lymph gland metastases from head and neck cancer; and two minor responses in patients with liver metastases from colorectal cancer. Plasma concentrations of FCE 23762 and its 13-dihydro metabolite, FCE 26176, were measured in 20 patients at doses 675 µg/m², using HPLC with fluorescence detection. The area under the plasma concentration-time curve ranged from 30 to 80 ng/h/ml; plasma data suggested linear kinetics in the range of tested doses (although there was considerable interpatient variability). The maximum tolerated dose defined in this study using this schedule is 1500 µg/m². A safe phase II dose for previously untreated patients using this schedule is 1250 µg/m²; however, this may actually be below the optimal dose for this patient population.

¹ To whom requests for reprints should be addressed.

Received 11/ 4/94. Accepted 3/17/95.

This article has been cited by other articles:

				L. Quintieri, C. Geroni, M. Fantin, R. Battaglia, A. Rosato, W. Speed, P. Zanovello, and M. Floreani Formation and Antitumor Activity of PNU-159682, A Major Metabolite of Nemorubicin in Human Liver Microsomes Clin. Cancer Res., February 15, 2005; 11(4): 1608 - 1617. [Abstract] [Full Text] [PDF]

				H. Lu and D. J. Waxman Antitumor Activity of Methoxymorpholinyl Doxorubicin: Potentiation by Cytochrome P450 3A Metabolism Mol. Pharmacol., January 1, 2005; 67(1): 212 - 219. [Abstract] [Full Text] [PDF]

				L. Quintieri, A. Rosato, E. Napoli, F. Sola, C. Geroni, M. Floreani, and P. Zanovello In Vivo Antitumor Activity and Host Toxicity of Methoxymorpholinyl Doxorubicin: Role of Cytochrome P450 3A Cancer Res., June 1, 2000; 60(12): 3232 - 3238. [Abstract] [Full Text]

				P. A. Vasey, S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. Murray, T. E. Hilditch, T. Murray, et al. Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents--Drug-Polymer Conjugates Clin. Cancer Res., January 1, 1999; 5(1): 83 - 94. [Abstract] [Full Text] [PDF]